Teva, P&G plan Indian venture; Novartis soothes Excedrin headache;

> In a joint venture, Proctor & Gamble ($PG) and Teva Pharmaceutical Industries ($TEVA) will reportedly invest $89 million to build a plant in Sanand, Gujarat, India, where Teva will make OTC products for the Vicks brand. Story

> Chris Viehbacher, CEO of Sanofi ($SNY), which closed a plant near Paris recently, says closing labs in Toulouse and Montpellier will be done "thoughtfully." Story

> The Senate took aim at the drug gray market, lashing out at some drug wholesalers and distributors it says are adding to the misery of drug shortages by "price gouging." Story
 
> A group of pain experts have asked the FDA to limit the claims and availability of opioids. Story

> Ingredientsmaker FMC BioPolymer says it will invest more than $100 million to build a new Avicel colloidal microcrystalline cellulose (MCC) manufacturing plant in Rayong, Thailand. Item

> GBI Research is predicting that the CMO market will more than double to $59.9 billion in 2018 as drugmakers outsource more work to Asia. Story

And Finally... In particularly good news for migraine sufferers, Novartis ($NVS) says on its Facebook page today that it has resumed production of Excedrin and it should return to store shelves in October. Story

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.